海特生物
(300683)
| 流通市值：40.62亿 | | | 总市值：43.56亿 |
| 流通股本：1.22亿 | | | 总股本：1.31亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 421,899,722.43 | 275,063,778.15 | 156,670,309 | 648,974,123.98 |
| 营业收入 | 421,899,722.43 | 275,063,778.15 | 156,670,309 | 648,974,123.98 |
| 二、营业总成本 | 513,069,856.75 | 334,849,647.86 | 172,864,987.49 | 740,494,897.94 |
| 营业成本 | 245,489,526.54 | 163,012,528.1 | 87,134,897.75 | 370,915,567.44 |
| 税金及附加 | 6,264,220.42 | 4,498,105.56 | 1,620,012.41 | 7,106,237.91 |
| 销售费用 | 115,714,645.74 | 72,508,253.72 | 34,403,013.64 | 126,606,515.33 |
| 管理费用 | 82,984,524.99 | 50,520,355.14 | 23,870,424.25 | 119,255,330.26 |
| 研发费用 | 66,329,154.95 | 46,724,213.72 | 27,012,145.01 | 121,745,047.2 |
| 财务费用 | -3,712,215.89 | -2,413,808.38 | -1,175,505.57 | -5,133,800.2 |
| 其中:利息费用 | 1,070,843.34 | 748,297.18 | 422,267.48 | 2,296,470.32 |
| 其中:利息收入 | 4,741,285.17 | 3,361,096.21 | 1,708,741.04 | 8,139,513.4 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,204,334.53 | 5,136,870.6 | 1,839,233.99 | -908,853.74 |
| 加:投资收益 | 13,027,945.93 | 12,692,210.67 | 402,759.96 | 16,698,740.87 |
| 资产处置收益 | -1,011,647.22 | -572.48 | - | -65,217.91 |
| 资产减值损失(新) | -105,576,119.74 | -7,169,132.8 | -3,125,407.5 | -21,146,957.28 |
| 信用减值损失(新) | 368,291.41 | 365,092.44 | 26,476.95 | -7,485,754.8 |
| 其他收益 | 8,580,423.24 | 6,009,086.75 | 2,219,943.3 | 28,718,757.03 |
| 四、营业利润 | -168,576,906.17 | -42,752,314.53 | -14,831,671.79 | -75,710,059.79 |
| 加:营业外收入 | 268,389.02 | 71,187.66 | 43,579.07 | 115,845.23 |
| 减:营业外支出 | 3,561,683.82 | 1,667,742.86 | 1,036,838.47 | 4,546,377.86 |
| 五、利润总额 | -171,870,200.97 | -44,348,869.73 | -15,824,931.19 | -80,140,592.42 |
| 减:所得税费用 | -10,987,759.89 | -4,146,490.23 | -1,407,076.48 | -6,370,727.96 |
| 六、净利润 | -160,882,441.08 | -40,202,379.5 | -14,417,854.71 | -73,769,864.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -160,882,441.08 | -40,202,379.5 | -14,417,854.71 | -73,769,864.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -158,092,654.78 | -39,179,909.35 | -13,930,370.19 | -69,348,658.66 |
| 少数股东损益 | -2,789,786.3 | -1,022,470.15 | -487,484.52 | -4,421,205.8 |
| 扣除非经常损益后的净利润 | -179,965,521.54 | -57,475,936.21 | -17,079,169.84 | -103,726,470.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.21 | -0.3 | -0.11 | -0.53 |
| (二)稀释每股收益 | -1.21 | -0.3 | -0.11 | -0.53 |
| 九、综合收益总额 | -160,882,441.08 | -40,202,379.5 | -14,417,854.71 | -73,769,864.46 |
| 归属于母公司股东的综合收益总额 | -158,092,654.78 | -39,179,909.35 | -13,930,370.19 | -69,348,658.66 |
| 归属于少数股东的综合收益总额 | -2,789,786.3 | -1,022,470.15 | -487,484.52 | -4,421,205.8 |
| 公告日期 | 2025-10-23 | 2025-08-26 | 2025-04-21 | 2025-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |